Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 1, 2020
Principal Event: Entry into a Material Definitive Agreement (Equity Distribution Agreement).
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or debt levels. It focuses on capital raising capacity.
- New Offering Capacity: Up to $40,000,000 in aggregate offering price.
- Previous Program Performance (Dec 2, 2019 – Dec 1, 2020): Sold 2,212,621 shares for gross proceeds of $10,641,934.
- Remaining Capacity (Old Program): $4,358,066 available under the 2019 Equity Distribution Agreement.
- Agent Commission: 3.0% of gross proceeds.
Material Changes
The Company entered into a new Equity Distribution Agreement with Canaccord Genuity LLC to replace the 2019 agreement once the latter is exhausted. This action expands the Company's ability to raise capital through "at the market" offerings, block transactions, or privately negotiated transactions.
Outlook, Risks, and Management Commentary
- Discretionary Sales: The Company is not obligated to sell any shares under the new agreement.
- Uncertainty: No assurance is given regarding the price, amount, or timing of any future sales.
- Termination: Either party may terminate the agreement with five days' notice; Canaccord Genuity may terminate under certain circumstances.
- Regulatory Status: Sales will be made under an effective shelf registration statement (Form S-3).
Investor Verification Checklist
- Verify the full text of the Equity Distribution Agreement (Exhibit 1.1) for specific conditions and termination clauses.
- Monitor future filings for actual share sales and pricing under the new $40 million program.
- Review the Company's cash position in subsequent 10-Q or 10-K filings to assess the necessity of utilizing this facility.
- Confirm the status of the remaining $4.36 million capacity under the 2019 agreement.